Business Wire

Exscientia Completes $100 million Series C Financing Round With BlackRock Funds

Share

Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. Including existing Series C investors, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital, the round totalled $100 million in funding.

This new capital will be used to support Exscientia’s platform development towards autonomous drug design. In addition, the company will extend its proprietary pipeline into clinical trials and expand existing capabilities in biological analytics that support target selection and portfolio development.

With the company’s end-to-end AI-first drug discovery platform, CentaurAI™, Exscientia has been able to generate novel drugs and overcome conventional drug discovery limitations several years faster than industry benchmarks. Exscientia has demonstrated the platform’s capabilities by creating the first fully AI-designed drug to enter clinical trials and advancing multiple drug candidates into preclinical testing. In addition to its growing proprietary pipeline, the company has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer and Dainippon Sumitomo as well as several biotech companies.

“Exscientia is breaking ground in small molecule drug design, with a platform that radically improves drug discovery” says William Abecassis, Head of BlackRock’s Innovation Capital who will join Exscientia’s Board of Directors as an observer. “We are thrilled to be investing in this world-class team, who are already delivering results with AI-designed drugs now entering clinical trials."

Andrew Hopkins, CEO of Exscientia added, “We are delighted that BlackRock shares our vision for revolutionising how drugs are discovered. It is also recognition of the ingenuity and hard work of our employees to turn the promise of AI into reality today, where we are bringing the world’s first AI designed drugs into the clinic. BlackRock’s investment is an important step in our vision that all drugs will be designed by AI. I believe that our company’s reimagined approach to drug discovery will become the new de facto standard.”

Exscientia has doubled in size over the past year and expects to double again in 2021, including a recent US expansion into Miami and Boston. The company employs over 100 people from over 20 different nations, with equal balance of technologists and drug discovery scientists, of which 60% are PhDs. Exscientia is named the fastest growing private biotech or pharmaceutical company in the UK in the 2021 Alantra Pharma Fast 50, as well as one of the fastest growing healthcare companies in the Financial Times FT1000.

ENDS

About Exscientia

Exscientia is an Artificial Intelligence (AI)-driven pharmatech committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform the how drugs are created.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI

Contact information

PR Contacts:
Edelman Public Relations:
Stephanie Crisp
P: +44 (0)75 8300 3417
stephanie.crisp@edelman.com

For Exscientia
Mark Swindells, Chief Commercial Officer
contact@exscientia.ai

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

XPRIZE and Musk Foundation Announce Guidelines and Open Registration for $100M XPRIZE Carbon Removal23.4.2021 01:23:00 CEST | Press release

XPRIZE, the global leader in designing and implementing innovative competition models to solve the world’s grand challenges, today announced the official launch of $100 Million XPRIZE Carbon Removal with the opening of team registration and the release of the competition guidelines. The announcement comes shortly after Peter H. Diamandis,XPRIZE founder and executive chairman, and Elon Musk sat down for a live stream hosted on Twitter to discuss the importance of spurring carbon removal solutions, the climate crisis, and the launch of the largest incentive prize in history. The conversation was followed by a virtual question and answer hosted by Marcius Extavour, vice president of climate and environment at XPRIZE, and XPRIZE’s chief impact officer, Zenia Tata. Funded by the Musk Foundation, $100M XPRIZE Carbon Removal is aimed at tackling climate change by asking global innovators to develop solutions that can pull carbon dioxide directly from the atmosphere or oceans and lock it away

Verimatrix To Participate in SportsPro Live Virtual Panel: How To Transform Physical Spaces into Digital Ecosystems22.4.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Lu Bolden, Chief Revenue Officer, is slated to participate in a SportsPro Live virtual panel discussion from 9:10 to 9:55 a.m. Central Time on Thursday, April 29. The event, which unites sports and technology professionals from across the globe, aims to prepare the industries for the future of sport. Bolden’s panel is slated to take place in the South Stand and discuss how technology can connect the in-venue experience to create more revenue opportunities. The group, moderated by Mike Bohndiek, CEO of PTI Digital Group, will also discuss what strategies and technologies can best deliver the new digital experiences. Other speakers on the panel include: Michael Cole, Chief Technology Officer, PGA European Tour and Ryder Cup Europe Adam Heintz, Senior Vice President, Business Intelligence, Monumental Sports & Entertainment “T

Rajeev Bhalla Named Director of Board at Next Level Aviation22.4.2021 17:39:00 CEST | Press release

Seasoned senior finance executive Rajeev Bhalla has been named a Director of the Board at Next Level Aviation, a leader in the aerospace used serviceable materials (USM) market. He brings wide-ranging financial, operational, and strategic expertise to the company as it plans substantial growth in the coming years, both organically and through acquisition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005834/en/ Rajeev Bhalla has been named Director of the Board of Next Level Aviation. He will help guide the company’s planned growth in the coming years, both organically and through acquisition. (Photo: Business Wire) Bhalla’s background includes demonstrated discipline and expertise in finance, governance, and team development. This comes through current work as a Cerberus Operating Partner, board of director roles as well as experience in a number of successful companies. Notably, those include: Circor International,

Medical Aesthetic Products’ Manufacturer Croma-Pharma Launches “Croma is More” E-Learning Series for Health Care Professionals22.4.2021 17:00:00 CEST | Press release

Croma-Pharma GmbH (Croma) always strives to support physicians in their work in the best possible way. For this reason, the company has developed an interactive e-learning platform with continuing education offerings for physicians working in the field of minimally invasive aesthetic. In this way, Croma aims to help health care professionals achieve sustainable growth and success in their medical clinics/practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005727/en/ Social Media Training for Health Care Professionals Copyright: Croma-Pharma GmbH (Graphic: Business Wire) Medical professionals can choose from a broad variety of different formats: Social Media & Online Marketing Facial Anatomy Workshops Aesthetic Startup Academy Aesthetic Excellence A variety of topics is presented by Industry experts. All the content comes with lifetime access hence the health care professionals can learn on their own schedule and

PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs22.4.2021 16:44:00 CEST | Press release

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region. The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (su

Xsolla Acquires Slemma, an Advanced Data Analytics and Visualization Company22.4.2021 16:00:00 CEST | Press release

Xsolla, the video game commerce company powered by its Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, has announced the acquisition of Slemma, an advanced data analytics and visualization reporting platform. The web-based tools allow users to create simple, easy-to-use and dynamic data reports with customizable dashboards. Xsolla will integrate Slemma’s product suite into the Publisher Account to provide clients with next-level data visualizations, even connecting to third party tools and services including Amazon RDS, Microsoft Azure, Google Analytics, Facebook, Twitter, Zendesk, Salesforce and many more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005443/en/ Xsolla acquires Slemma, a robust data analytics and visualization platform. (Graphic: Business Wire) “Everything we do at Xsolla focuses on providing the best experience, tools

Serie A Club Parma Calcio Signs Deal with Stats Perform for Access to the Most Sophisticated Player Identification Tool—Edge Recruitment22.4.2021 15:49:00 CEST | Press release

Today, Stats Perform, the sports tech leader in data and AI, announced a deal with Italian football club Parma Calcio, recently purchased by Iowa-based Krause Group, which will see the Serie A side become the first club worldwide to access the innovative Edge Recruitment platform, the industry’s most sophisticated player identification tool. Since the emergence of technical scouting during the mid-2000s, recruitment analysts have been using data to assess prospects through the lens of traditional on-field position labels. Launched earlier this season, Edge Recruitment introduces a new method of assessing players, applying multiple AI-powered models to profile players based on their role in a team. At the heart of Edge Recruitment is Role Discovery, a model which detects 18 different types of role all over the pitch based on a player’s spatial tendencies, contributions to different phases of play, possession involvement, distribution and shooting tendencies. Through applying Role Discov